H.C. Wainwright Downgrades Shattuck Labs (STTK) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
TD Cowen Reiterates Buy Rating on Shattuck Labs (STTK)
October 1, 2024 9:28 AM UTCTD Cowen analyst Marc Frahm reiterated a Buy on Shattuck Labs (NASDAQ: STTK).
The analyst commented, "STTK has discontinued the SL-172154 program in HR-MDS/AML based on uncompelling OS separation vs. historical controls. The company is pivoting to a series of anti-DR3... More
Shattuck Labs (STTK) Provides Company Update and Announces SL-325
October 1, 2024 6:32 AM UTCShattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with cancer and chronic immune-related diseases, today announced a strategic pipeline prioritization to include the discontinuation of its clinical program, SL-172154. The Company will turn its focus to SL-325, its DR3 antagonist antibody, and plans initial clinical development in patients with IBD, where TL1A/DR3 blocking antibodies have demonstrated compelling monotherapy efficacy.
We are disappointed that the promising complete remission rates we... More
